AbbVie Inc.
ABBV · CIK 0001551152 · Pharmaceutical Preparations
About AbbVie Inc.
Overview AbbVie or "the company" refer to AbbVie Inc., or AbbVie Inc. and its consolidated subsidiaries, as the context requires. AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, neuroscience, oncology and aesthetics.
Business information sourced from SEC annual filing filed Feb 20, 2026. Business descriptions reflect the cited filing and may not describe subsequent changes.
Company identification is based on SEC registration information. Financial figures are sourced from SEC filings.
Financial highlights
Latest qualifying annual SEC observations · USDHistorical financial performance
USD billions · Annual SEC observations · Choose a metric
Each metric uses a consistent SEC accounting concept when available. Fiscal year-end dates may differ across metrics. Negative values are displayed with a minus sign.
Annual financial history
USD · Exact fiscal period ends| Period ended | Revenue | Net income | Operating income | Assets | Liabilities | Cash | Operating cash flow | Net margin |
|---|---|---|---|---|---|---|---|---|
| Dec. 31, 2025 | $61.16B | $4.23B | $15.08B | $133.96B | — | $5.23B | $19.03B | 6.9% |
| Dec. 31, 2024 | $56.33B | $4.28B | $9.14B | $135.16B | — | $5.52B | $18.81B | 7.6% |
| Dec. 31, 2023 | $54.32B | $4.86B | $12.76B | $134.71B | — | $12.81B | $22.84B | 9.0% |
| Dec. 31, 2022 | $58.05B | $11.84B | $18.12B | $138.80B | — | $9.20B | $24.94B | 20.4% |
| Dec. 31, 2021 | $56.20B | $11.54B | $17.92B | $146.53B | — | $9.75B | $22.78B | 20.5% |
| Dec. 31, 2020 | $45.80B | $4.62B | $11.36B | $150.56B | — | $8.45B | $17.59B | 10.1% |
| Dec. 31, 2019 | $33.27B | $7.88B | $12.98B | $89.12B | — | $39.92B | $13.32B | 23.7% |
| Dec. 31, 2018 | $32.75B | $5.69B | $6.38B | $59.35B | — | $7.29B | $13.43B | 17.4% |
A dash indicates unavailable or nonmatching period data. Figures are SEC observations, not estimates.
Company information
- Registered name
- AbbVie Inc.
- Ticker symbol
- ABBV
- CIK
- 0001551152
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC SIC code
- 2834
- Fiscal year end (MMDD)
- 1231
- Last SEC synchronization
- Nov 7, 2026 14:55 UTC
- Headquarters / business address
- 1 NORTH WAUKEGAN ROAD
NORTH CHICAGO, IL 60064 - Mailing address
- 1 NORTH WAUKEGAN ROAD
NORTH CHICAGO, IL 60064 - Business phone
- (847) 932-7900
Company contact information is drawn from SEC submissions, where reported, and may not reflect current operating locations. Last company information check: Nov 7, 2026 20:22 UTC. Official website, business descriptions and executive details require separate verification.
Latest SEC filings
Browse filings →| Form | Filed | Report period | Official source |
|---|---|---|---|
| 10-Q | Nov. 3, 2026 | Sept. 30, 2026 | View SEC filing ↗ |
| 8-K | Nov. 2, 2026 | Oct. 28, 2026 | View SEC filing ↗ |
| 8-K | Oct. 30, 2026 | Oct. 30, 2026 | View SEC filing ↗ |
| 3 | Oct. 23, 2026 | Oct. 14, 2026 | View SEC filing ↗ |
| 8-K | Oct. 15, 2026 | Oct. 14, 2026 | View SEC filing ↗ |
| 8-K | Oct. 5, 2026 | Oct. 5, 2026 | View SEC filing ↗ |
| 4 | Oct. 2, 2026 | Sept. 30, 2026 | View SEC filing ↗ |
| 4 | Oct. 2, 2026 | Sept. 30, 2026 | View SEC filing ↗ |
| 8-K | Sept. 3, 2026 | Sept. 3, 2026 | View SEC filing ↗ |
| 8-K | Aug. 18, 2026 | Aug. 18, 2026 | View SEC filing ↗ |
| 4 | Aug. 18, 2026 | Aug. 14, 2026 | View SEC filing ↗ |
| 144 | Aug. 14, 2026 | View SEC filing ↗ | |
| 424B5 | Aug. 6, 2026 | View SEC filing ↗ | |
| FWP | Aug. 5, 2026 | View SEC filing ↗ | |
| 8-K | Aug. 5, 2026 | Aug. 4, 2026 | View SEC filing ↗ |
| 424B5 | Aug. 4, 2026 | View SEC filing ↗ | |
| 10-Q | Aug. 3, 2026 | June 30, 2026 | View SEC filing ↗ |
| 8-K | July 31, 2026 | July 31, 2026 | View SEC filing ↗ |
| 8-K | July 6, 2026 | July 6, 2026 | View SEC filing ↗ |
| 4 | July 2, 2026 | June 30, 2026 | View SEC filing ↗ |
Financial data is provided for informational purposes, not investment advice. Observations may include restatements; review original SEC filings before making decisions.